These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 12790697)

  • 1. Saquinavir: a review of its use in boosted regimens for treating HIV infection.
    Plosker GL; Scott LJ
    Drugs; 2003; 63(12):1299-324. PubMed ID: 12790697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    Cvetkovic RS; Goa KL
    Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Darunavir: a review of its use in the management of HIV infection in adults.
    McKeage K; Perry CM; Keam SJ
    Drugs; 2009; 69(4):477-503. PubMed ID: 19323590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Saquinavir soft-gel capsule: an updated review of its use in the management of HIV infection.
    Figgitt DP; Plosker GL
    Drugs; 2000 Aug; 60(2):481-516. PubMed ID: 10983742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
    HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.
    Chetchotisakd P; Anunnatsiri S; Mootsikapun P; Kiertiburanakul S; Anekthananon T; Bowonwatanuwong C; Kowadisaiburana B; Supparatpinyo K; Ruxrungtham K;
    HIV Med; 2007 Nov; 8(8):529-35. PubMed ID: 17944686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nelfinavir: an update on its use in HIV infection.
    Bardsley-Elliot A; Plosker GL
    Drugs; 2000 Mar; 59(3):581-620. PubMed ID: 10776836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, efficacy and pharmacokinetics of ritonavir 400mg/saquinavir 400mg twice daily plus rifampicin combined therapy in HIV patients with tuberculosis.
    Rolla VC; da Silva Vieira MA; Pereira Pinto D; Lourenço MC; de Jesus Cda S; Gonçalves Morgado M; Ferreira Filho M; Werneck-Barroso E
    Clin Drug Investig; 2006; 26(8):469-79. PubMed ID: 17163279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pilot study of saquinavir and lopinavir/ritonavir twice daily in protease inhibitor-naive HIV-positive patients.
    Hellinger J; Cohen C; Morris A; Sheble-Hall S; Gordon D; Foy C; Jackson-Pope L; Shevitz A; van Schaic E
    HIV Clin Trials; 2005; 6(2):107-17. PubMed ID: 15983895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nelfinavir. A review of its therapeutic efficacy in HIV infection.
    Jarvis B; Faulds D
    Drugs; 1998 Jul; 56(1):147-67. PubMed ID: 9664204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study.
    Cardiello PG; van Heeswijk RP; Hassink EA; Srasuebkul P; Mahanontharit A; Samor TM; Worarien W; Beijnen JH; Hoetelmans RM; Ruxrungtham K; Cooper DA; Lange JM; Phanuphak P
    J Acquir Immune Defic Syndr; 2002 Apr; 29(5):464-70. PubMed ID: 11981362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
    Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; Bernstein B; Hanna GJ
    J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.
    Staszewski S; Babacan E; Stephan C; Haberl A; Carlebach A; Gute P; Klauke S; Hermschulte Y; Stuermer M; Dauer B;
    J Antimicrob Chemother; 2006 Nov; 58(5):1024-30. PubMed ID: 16956902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ritonavir/saquinavir plus one nucleoside reverse transcriptase inhibitor (NRTI) versus indinavir plus two NRTIs in protease inhibitor-naive HIV-1-infected adults (IRIS study).
    Florence E; Dreezen C; Desmet P; Smets E; Fransen K; Vandercam B; Pelgrom J; Clumeck N; Colebunder R
    Antivir Ther; 2001 Dec; 6(4):255-62. PubMed ID: 11878407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delavirdine: a review of its use in HIV infection.
    Scott LJ; Perry CM
    Drugs; 2000 Dec; 60(6):1411-44. PubMed ID: 11152019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ritonavir and saquinavir combination therapy for the treatment of HIV infection.
    Cameron DW; Japour AJ; Xu Y; Hsu A; Mellors J; Farthing C; Cohen C; Poretz D; Markowitz M; Follansbee S; Angel JB; McMahon D; Ho D; Devanarayan V; Rode R; Salgo M; Kempf DJ; Granneman R; Leonard JM; Sun E
    AIDS; 1999 Feb; 13(2):213-24. PubMed ID: 10202827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The choice of HIV protease inhibitor: indinavir is currently the best option.
    Prescrire Int; 1999 Apr; 8(40):55-60. PubMed ID: 10848067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Saquinavir soft-gel capsule formulation. A review of its use in patients with HIV infection.
    Perry CM; Noble S
    Drugs; 1998 Mar; 55(3):461-86. PubMed ID: 9530549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose saquinavir plus ritonavir: long-term efficacy in HIV-positive protease inhibitor-experienced patients and predictors of virologic response.
    Paredes R; Puig T; Arnó A; Negredo E; Balagué M; Bonjoch A; Jou A; Tuldrà A; Tural C; Sirera G; Veny A; Romeu J; Ruiz L; Clotet B
    J Acquir Immune Defic Syndr; 1999 Oct; 22(2):132-8. PubMed ID: 10843526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.